Indeed, the use of AKR1C3 or ALDH3A1 inhibitors has been showing evident therapeutic benefits in preclinical research, highlighting their potential application value in the endeavor towards tumor treatment [55, 56]. Here, ALDH3A1 is linked to neoplasm.